PriceSensitive

Biome Australia (ASX:BIO) signs distribution agreement with Priceline Pharmacy

ASX News, Health Care
ASX:BIO      MCAP $59.59M
30 May 2022 08:28 (AEST)

This browser does not support the video element.

Biome Australia’s (BIO) activated probiotics are set to be sold in Priceline pharmacies across Australia after signing a distribution agreement.

The microbiome health company signed the agreement with Australian Pharmaceutical Industries (API) — of which Priceline is a subsidiary — to sell the probiotics as core range in 370 pharmacies, with an initial allocation of the product range to be sold between June and July this year.

The company said the new partnership will have a positive impact on revenue growth, with access to new accounts and customers, and growing to 3000 distribution points — a 50 per cent increase since Biome’s IPO on November 30, 2021.

The move has also been backed by API’s new owners Wesfarmers Group (WES).

“Distribution of Biome’s flagship Activated Probiotics product range via Priceline Pharmacy presents an exciting opportunity for us to impact more patient lives in Australian communities,” Biome Australia Managing Director Blair Norfolk said.

“We are proud to support the evolving health service focus of Priceline Pharmacy with our Activated Probiotics practitioner-only range.”

Meanwhile, Priceline Pharmacy General Manager Andrew Vidler said Biome’s probiotic product range adds to the pharmaceutical chain’s health proposition for customers.

“We know that Australians want to make informed decisions about their health, and as a result, are increasingly seeking scientifically-backed products to support their health aspirations,” Mr Vidler said.

Biome Australia shares were up 10 per cent, trading at 11 cents at 12:07 pm AEST.

Related News